Monitoring
16
Monitoring of Testosterone Replacement Therapy
➤ In hypogonadal men who have started testosterone therapy, ES
recommends evaluating the patient after treatment initiation to
assess whether the patient has responded to treatment, is suffering
any adverse effects, and is complying with the treatment regimen.
(Ungraded Good Practice Statement)
➤ ES recommends a urological consultation for hypogonadal men
receiving testosterone treatment if during the first 12 months of
testosterone treatment there is a confirmed increase in prostate-
specific antigen concentration >1.4 ng/mL above baseline, a
confirmed prostate-specific antigen >4.0 ng/mL, or a prostatic
abnormality detected on digital rectal examination. After 1 year,
prostate monitoring should conform to standard guidelines for
prostate cancer screening based on the race and age of the patient.
(2|⊕⊕
)
